Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$4.80 | -$4.80 | -$4.80 |
| Q2 2025 | 2 | -$4.68 | -$4.55 | -$4.62 |
| Q3 2025 | 2 | -$4.39 | -$3.58 | -$3.98 |
| Q4 2025 | 2 | -$2.80 | -$2.52 | -$2.66 |
| Q1 2026 | 2 | -$2.49 | -$2.42 | -$2.46 |
| Q2 2026 | 1 | -$2.60 | -$2.60 | -$2.60 |
| Q3 2026 | 1 | -$2.78 | -$2.78 | -$2.78 |
| Q4 2026 | 1 | -$2.90 | -$2.90 | -$2.90 |
NextCure, Inc. last posted its earnings results on Wednesday, November 5th, 2025. The company reported $-3.22 earnings per share for the quarter, topping analysts' consensus estimates of $-4.06 by $0.84. The company had revenue of 0 for the quarter and had revenue of 0 for the year. NextCure, Inc. has generated $-24 earnings per share over the last year ($-23.88 diluted earnings per share) and currently has a price-to-earnings ratio of -0.5. NextCure, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 26th, 2026 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/05/2025 | Q3 2025 | -$4.06 | -$3.22 | 0.84 | $0 | $0 |
| 08/07/2025 | Q2 2025 | -$4.62 | -$11.29 | -6.67 | $0 | $0 |
| 05/01/2025 | Q1 2025 | -$4.80 | -$4.70 | 0.1 | $0 | $0 |
| 03/06/2025 | Q4 2024 | -$0.34 | -$4.97 | -4.63 | $0 | $0 |
| 11/07/2024 | Q3 2024 | -$0.35 | -$4.95 | -4.6 | $0 | $0 |
| 08/01/2024 | Q2 2024 | -$0.36 | -$6.61 | -6.25 | $0 | $0 |
| 05/02/2024 | Q1 2024 | -$0.45 | -$7.36 | -6.91 | N/A | $0 |
| 03/21/2024 | Q4 2023 | -$0.54 | -$6.22 | -5.68 | N/A | $0 |
| 11/02/2023 | Q3 2023 | -$0.64 | -$6.16 | -5.52 | N/A | $0 |
| 08/03/2023 | Q2 2023 | -$0.60 | -$7.70 | -7.1 | N/A | $0 |
| 05/04/2023 | Q1 2023 | -$0.64 | -$6.95 | -6.31 | N/A | $0 |
| 03/02/2023 | Q4 2022 | -$0.65 | -$7.47 | -6.82 | N/A | $0 |
| 11/03/2022 | Q3 2022 | -$0.60 | -$8.18 | -7.58 | N/A | $0 |
| 08/04/2022 | Q2 2022 | -$0.73 | -$7.75 | -7.02 | N/A | $0 |
| 05/05/2022 | Q1 2022 | -$0.68 | -$8.92 | -8.24 | N/A | $0 |
| 03/03/2022 | Q4 2021 | -$0.67 | -$7.35 | -6.68 | N/A | $0 |
| 11/04/2021 | Q3 2021 | -$0.67 | -$7.79 | -7.12 | N/A | $0 |
| 08/05/2021 | Q2 2021 | -$0.60 | -$7.82 | -7.22 | N/A | $0 |
| 05/06/2021 | Q1 2021 | -$0.57 | -$7.19 | -6.62 | N/A | $0 |
| 03/04/2021 | Q4 2020 | -$0.58 | -$6.73 | -6.15 | N/A | $0 |
NextCure, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 26th, 2026 based offlast year's report dates.
In the previous quarter, NextCure, Inc. (:NXTC) reported $-3.22 earnings per share (EPS) to beat the analysts' consensus estimate of $-4.06 by $0.84.
The conference call for NextCure, Inc.'s latest earnings report can be listened to online.
The conference call transcript for NextCure, Inc.'s latest earnings report can be read online.
NextCure, Inc. (:NXTC) has a recorded net income of $-55,654,000.NextCure, Inc. has generated $-23.88 earnings per share over the last four quarters.
NextCure, Inc. (:NXTC) has a price-to-earnings ratio of -0.5 and price/earnings-to-growth ratio is 0.02.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED